Ceftiofur (Naxcel / Excenel)

Ceftiofur is a third-generation cephalosporin antibiotic specifically developed for veterinary use, making it one of the few antibiotics in this class approved for use in animals including dogs. Marketed under brand names including Naxcel and Excenel, ceftiofur provides broad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria commonly responsible for infections in dogs. As a veterinary-specific antibiotic, ceftiofur has been formulated and studied specifically for animal patients, providing veterinarians with confidence in its safety and efficacy profile when treating canine bacterial infections. The drug has become an important tool in veterinary medicine for treating a variety of bacterial infections in dogs.

Ceftiofur works through the same bactericidal mechanism as other cephalosporin antibiotics, interfering with bacterial cell wall synthesis to cause bacterial death. The drug binds to penicillin-binding proteins within the bacterial cell, preventing the formation of proper cross-links in the peptidoglycan layer that provides structural integrity to the cell wall. Without a properly formed cell wall, bacteria cannot survive and undergo lysis. This mechanism makes ceftiofur effective at killing bacteria rather than simply inhibiting their growth, which is particularly important for clearing infections effectively. The drug's activity against a broad range of pathogens makes it suitable for treating infections in multiple body systems.

Ceftiofur is available in several injectable formulations designed for veterinary use. The crystalline free acid formulation, sold as Excenel RTU, provides extended-release activity that allows for less frequent dosing. The standard formulation requires more frequent administration but provides flexibility in dosing. All ceftiofur products are administered by injection, typically subcutaneously, which ensures reliable drug absorption and therapeutic blood levels. The injectable route of administration means that ceftiofur is usually administered by veterinary professionals, though some pet owners may be trained to give injections at home for longer treatment courses.

As a prescription veterinary medication, ceftiofur requires veterinary supervision for proper use in dogs. The drug has been shown to be well-tolerated in dogs when used according to labeled directions, with a safety profile that makes it suitable for a variety of patients. Proper dosing based on body weight is essential, and the veterinarian will determine the appropriate dose and duration of treatment based on the type of infection being treated. Like all antibiotics, ceftiofur should be used responsibly to maintain its effectiveness and minimize the development of bacterial resistance, which is a growing concern in both human and veterinary medicine.

Ceftiofur is approved for the treatment of canine urinary tract infections caused by susceptible strains of Escherichia coli and Proteus mirabilis, two of the most common bacterial pathogens responsible for UTIs in dogs. Urinary tract infections are among the most frequently diagnosed bacterial infections in veterinary practice, and ceftiofur provides an effective injectable option for dogs that cannot take oral medications or when reliable antibiotic administration is essential. The drug achieves therapeutic concentrations in urine, making it well-suited for treating infections in the urinary system. Dogs with recurrent UTIs or those caused by organisms resistant to first-line oral antibiotics may benefit from ceftiofur therapy.

Respiratory tract infections represent another primary indication for ceftiofur use in dogs. The drug is effective against many bacteria that cause pneumonia, bronchitis, and upper respiratory infections in canine patients. Respiratory infections can range from mild to life-threatening, and the broad-spectrum activity of ceftiofur makes it a reliable choice when the causative organism has not yet been identified or when culture results indicate susceptibility. Dogs hospitalized with severe pneumonia may receive ceftiofur as part of their antibiotic regimen, and the injectable formulation ensures consistent drug delivery even in patients that are too ill to eat or take oral medications.

Skin and soft tissue infections are commonly treated with ceftiofur when susceptible organisms are involved. Dogs frequently develop skin infections secondary to wounds, allergic skin disease, or other underlying conditions. These infections may involve the superficial skin layers or extend deeper into the soft tissues, causing cellulitis or abscesses. Ceftiofur's activity against Staphylococcus and Streptococcus species, as well as gram-negative pathogens, makes it effective for many skin infections. The extended-release formulation is particularly convenient for treating skin infections as it allows for less frequent injections while maintaining therapeutic drug levels.

Postoperative infection prevention and treatment is another application for ceftiofur in veterinary practice. Dogs undergoing surgical procedures may receive ceftiofur as prophylaxis against surgical site infections, particularly for procedures involving contaminated tissues or in patients at higher risk for infection. When postoperative infections do develop, ceftiofur can be used therapeutically to clear the bacterial infection and promote healing. The reliable parenteral administration ensures that postoperative patients receive consistent antibiotic coverage even if they have reduced appetite or difficulty taking oral medications during their recovery.

Veterinarians may select ceftiofur based on culture and sensitivity testing that demonstrates the infecting organism is susceptible to the drug. The choice of ceftiofur over other antibiotics may also be influenced by the need for injectable administration, the convenience of extended-release formulations, or the specific spectrum of activity required for the patient's infection. As a veterinary-approved product, ceftiofur comes with established dosing guidelines for dogs, giving veterinarians confidence in its use. The medication is particularly valuable in situations where compliance with oral antibiotic administration is uncertain or when the severity of infection warrants parenteral therapy.

Dosing of ceftiofur in dogs is determined by the veterinarian based on the specific formulation used, the type and severity of infection, and the individual patient's characteristics including body weight and overall health status. Because different ceftiofur products have different concentrations and release profiles, it is essential that the prescribed dosing regimen matches the specific product being used. The veterinarian will provide detailed instructions for the dosing protocol, and these instructions should be followed exactly to ensure optimal treatment outcomes. Accurate weight measurement is important for calculating the correct dose.

For the standard ceftiofur sodium formulation, typical dosing in dogs ranges from 2.2 to 4.4 milligrams per kilogram of body weight, administered subcutaneously once daily. The specific dose within this range depends on the severity of infection and the susceptibility of the causative organism. Treatment duration typically ranges from five to fourteen days depending on the clinical response and type of infection being treated. Some infections may require longer treatment courses, and the veterinarian will determine the appropriate duration based on the patient's progress and follow-up examinations.

The ceftiofur crystalline free acid formulation, marketed as Excenel RTU, provides extended-release activity that allows for less frequent dosing. A single injection of this formulation can provide therapeutic drug levels for several days, reducing the number of injections required during the treatment course. This is particularly advantageous for dogs that are difficult to inject, for clients with limited ability to bring pets in for frequent treatments, or when minimizing handling stress is desirable. The extended-release formulation may be administered as a single injection or repeated based on clinical response and veterinary guidance.

Ceftiofur is administered by subcutaneous injection, typically in the loose skin over the shoulder blades or along the side of the chest. The veterinary team will identify the appropriate injection site and demonstrate proper technique if home administration is planned. The injection site should be rotated if multiple injections are required to minimize local irritation. The area should be clean and dry before injection, and the medication should be at room temperature to minimize discomfort. Following injection, gentle massage of the site can help distribute the medication.

If a dose of ceftiofur is missed, the owner should contact the veterinarian for guidance on how to proceed. For once-daily standard formulations, the missed dose should generally be given as soon as remembered unless it is close to the time for the next scheduled dose. For extended-release formulations, the timing of any additional doses will be determined by the veterinarian based on the drug's pharmacokinetics. Doubling doses is not recommended and could increase the risk of adverse effects.

Completing the full prescribed course of ceftiofur is essential even if the dog appears to have recovered before the antibiotic course is finished. Stopping treatment early can allow surviving bacteria to repopulate and may contribute to the development of antibiotic-resistant organisms. If concern exists about continuing treatment due to adverse effects or other issues, the veterinarian should be consulted before discontinuing the medication. Follow-up appointments allow the veterinarian to assess treatment response and determine whether the infection has been fully resolved.

Ceftiofur is generally well-tolerated in dogs when used according to labeled directions, with most patients completing their treatment course without experiencing significant adverse effects. As a cephalosporin antibiotic specifically developed for veterinary use, ceftiofur has been evaluated for safety in dogs, and its side effect profile is consistent with other members of the beta-lactam antibiotic class. However, as with any medication, individual dogs may experience adverse reactions, and owners should be aware of potential side effects to watch for during treatment.

The most commonly reported side effects of ceftiofur in dogs involve local reactions at the injection site. Dogs may experience mild pain, swelling, or irritation where the medication is administered. These local reactions are typically transient and resolve without treatment within a few days. The extended-release formulation may cause more pronounced local reactions due to the nature of the crystalline free acid suspension. Rotating injection sites when multiple injections are required can help minimize cumulative local irritation. If injection site reactions become severe or do not resolve, the veterinarian should be notified.

Gastrointestinal effects may occur in some dogs receiving ceftiofur, though these are generally less common than with oral antibiotics. Dogs may experience decreased appetite, nausea, vomiting, or diarrhea during treatment. These effects are typically mild and self-limiting. Antibiotic therapy can disrupt the normal bacterial flora of the intestinal tract, potentially leading to digestive upset or secondary infections. Probiotic supplementation during or after antibiotic therapy may help maintain healthy intestinal bacteria. Severe or persistent gastrointestinal symptoms should be reported to the veterinarian.

Allergic reactions to ceftiofur can occur, particularly in dogs with a history of hypersensitivity to cephalosporin or penicillin antibiotics. Signs of allergic reaction may include hives, facial swelling, itching, or difficulty breathing. Anaphylactic reactions, while rare, represent a medical emergency and require immediate veterinary attention. Dogs with known allergies to beta-lactam antibiotics should not receive ceftiofur, and any dog receiving the medication for the first time should be monitored for signs of allergic response. Owners should inform the veterinarian of any previous adverse reactions to antibiotics.

Rare side effects of ceftiofur may include changes in blood cell counts or liver enzyme elevations, which are typically detected through blood work monitoring rather than obvious clinical signs. These effects are uncommon and usually reversible upon discontinuation of the medication. Any concerning changes in behavior, appetite, energy level, urination, or stool character during treatment should prompt contact with the veterinarian. Dogs experiencing difficulty breathing, collapse, severe swelling, bloody stool or vomit, or other alarming symptoms should receive immediate emergency veterinary care.

The primary contraindication for ceftiofur use is known hypersensitivity to cephalosporin antibiotics or to penicillin and related beta-lactam antibiotics. Cross-reactivity between penicillins and cephalosporins can occur, and dogs that have experienced allergic reactions to any member of these antibiotic classes should not receive ceftiofur. Allergic reactions can range from mild skin reactions to severe anaphylaxis, which can be life-threatening. A thorough medication history should be obtained before initiating therapy, and owners should inform the veterinarian of any previous adverse reactions to antibiotics or other medications.

Dogs with severe kidney impairment require careful evaluation before ceftiofur administration. While ceftiofur is primarily metabolized to an active metabolite that is eliminated through both the kidneys and biliary system, significant renal dysfunction can affect drug elimination and potentially lead to accumulation. Dose adjustments may be necessary in dogs with compromised kidney function, and the veterinarian will assess kidney status before prescribing the medication. Blood work to evaluate kidney function may be performed before and during treatment in dogs with known or suspected renal disease.

Pregnancy and lactation considerations apply to ceftiofur use, though the drug is often considered relatively safe during pregnancy compared to some other antibiotics. Ceftiofur crosses the placenta and may be present in milk, potentially affecting developing fetuses or nursing puppies. The decision to use ceftiofur in pregnant or nursing dogs involves weighing the benefits of treating the mother's infection against any theoretical risks to the offspring. In many cases, untreated infections pose a greater risk to both mother and puppies than the antibiotic itself. Young puppies may have different pharmacokinetic profiles than adult dogs due to developing organ function.

Other medical conditions that may influence ceftiofur use include bleeding disorders and a history of gastrointestinal disease, particularly antibiotic-associated diarrhea or colitis. While ceftiofur is not specifically associated with bleeding complications, monitoring may be appropriate in dogs with pre-existing coagulation abnormalities. Dogs with a history of severe gastrointestinal reactions to antibiotics may be at increased risk for digestive upset with ceftiofur. Complete disclosure of the dog's medical history, including all current and past health conditions, allows the veterinarian to make informed decisions about antibiotic selection and to anticipate potential complications.

Providing the veterinarian with a complete list of all medications, supplements, and treatments the dog is receiving is essential before starting ceftiofur therapy. Drug interactions can affect how ceftiofur works, potentially altering its effectiveness or increasing the risk of adverse effects. This comprehensive list should include prescription medications, over-the-counter products, herbal supplements, vitamins, and any topical treatments being used. Even products that may seem unrelated to antibiotic therapy could have important interactions.

Potential interactions of clinical significance with ceftiofur include the concurrent use of nephrotoxic medications, particularly aminoglycoside antibiotics such as gentamicin or amikacin. While cephalosporins and aminoglycosides are sometimes used together to provide synergistic antibacterial effects, the combination can increase the risk of kidney toxicity. If both drug classes are needed, careful monitoring of kidney function through blood tests and urine analysis is important. Maintaining adequate hydration helps support kidney function during combination therapy. Loop diuretics may also increase nephrotoxicity risk when combined with cephalosporin antibiotics.

Probenecid can interact with cephalosporin antibiotics by decreasing their elimination through the kidneys, leading to higher and more prolonged blood levels. While probenecid is rarely used in veterinary medicine, any medication that affects kidney tubular secretion could potentially interact with ceftiofur. Nonsteroidal anti-inflammatory drugs are commonly used in dogs and may have additive effects on kidney function when combined with antibiotics, though this interaction is generally of low clinical significance in dogs with normal kidney function. The veterinarian will consider all concurrent medications when developing the treatment plan.

Because ceftiofur is administered by injection rather than orally, food-drug interactions are not a significant concern. However, any oral medications or supplements the dog is receiving should still be disclosed. Probiotic supplements may be beneficial to maintain intestinal health during antibiotic therapy and are typically given at different times than antibiotic doses to maximize their effectiveness. Herbal supplements with antimicrobial properties might theoretically interact with antibiotic therapy, and their use should be discussed with the veterinarian. Overall, ceftiofur has relatively few significant drug interactions, but comprehensive medication disclosure allows for optimal treatment planning and monitoring.

Standard precautions for ceftiofur use include ensuring accurate body weight measurement for dose calculation and confirming that the dog has no history of allergic reactions to cephalosporin or penicillin antibiotics. The veterinarian will perform a physical examination and may obtain blood work before initiating treatment to establish baseline values and identify any underlying conditions that could affect drug safety. Owners should follow all dosing instructions precisely, including timing and route of administration, to optimize treatment effectiveness.

Breed-specific considerations for ceftiofur are generally limited, as the drug does not appear to be affected by the MDR1 gene mutation that impacts certain medications in herding breeds. However, comprehensive patient assessment includes awareness of any breed-related health tendencies that could affect treatment. Breeds predisposed to kidney disease, for example, may require closer monitoring during antibiotic therapy. Collies, Australian Shepherds, Shetland Sheepdogs, and related breeds with potential MDR1 mutations can safely receive ceftiofur, but other medications in their treatment regimen should be evaluated for MDR1 concerns.

Safe handling of ceftiofur requires appropriate precautions for both the person administering the medication and other household members. Individuals with known allergies to penicillin or cephalosporin antibiotics should avoid handling the drug, as sensitization can occur through skin contact. Gloves should be worn during preparation and administration, and hands should be washed thoroughly afterward. The medication should be kept in its original packaging until use and stored according to labeled directions. Used syringes and needles require proper disposal in sharps containers.

Monitoring during ceftiofur treatment involves watching for both signs of treatment response and potential adverse effects. Improvement in clinical signs such as resolution of fever, improved appetite, and resolution of specific infection symptoms indicates positive response to therapy. Worsening of symptoms, development of new problems, or failure to improve may indicate the need for treatment reassessment. Local reactions at injection sites should be monitored, and any concerning injection site abnormalities should be reported. Blood work monitoring may be recommended for prolonged treatment courses.

Special populations requiring additional consideration include geriatric dogs, who may have age-related changes in organ function even without obvious disease, and puppies whose organ systems are still developing. Senior dogs may benefit from kidney function assessment before treatment. Very young puppies may metabolize drugs differently than adults and may require adjusted dosing. Dogs with concurrent diseases, particularly those affecting the kidneys or immune system, require careful monitoring throughout therapy. The veterinarian will tailor the treatment approach based on the individual patient's characteristics and risk factors.

Proper storage of ceftiofur is essential to maintain the drug's effectiveness and stability. Storage requirements vary between different ceftiofur formulations, so it is important to follow the specific instructions provided with the product being used. The ceftiofur sodium powder for reconstitution should be stored at controlled room temperature and protected from light. Once reconstituted, stability is limited, and the solution should be used within the timeframe specified by the manufacturer or discarded. The crystalline free acid suspension has different storage requirements and should be stored according to its labeled directions.

The extended-release ceftiofur crystalline free acid formulation should be stored in the refrigerator at 36 to 46 degrees Fahrenheit until use. The product should be brought to room temperature before administration to minimize injection discomfort and ensure proper flow characteristics. Once removed from refrigeration, the product should be shaken well before drawing up the dose. Unused portions should be returned to the refrigerator promptly. The medication should not be frozen, and any product that has been frozen should be discarded. Expiration dates should be checked before each use.

Safe handling and disposal of ceftiofur require attention to protecting both people and the environment. As noted, individuals with allergies to beta-lactam antibiotics should avoid handling these medications. All injection supplies including syringes, needles, and used vials should be disposed of properly in designated sharps containers. These containers should not be placed in regular household trash. Unused medication should be returned to the veterinary clinic or pharmacy for proper disposal rather than flushed or thrown away. Many veterinary practices participate in medication disposal programs. Proper storage also means keeping the medication secure and out of reach of children and pets, though the injectable nature of ceftiofur makes accidental ingestion unlikely.

Ceftiofur is generally safe and effective for use in dogs of all breeds when prescribed and administered appropriately. The drug's pharmacokinetics do not appear to vary significantly among different dog breeds, and standard weight-based dosing applies across the range of canine body sizes. Individual variation in drug response can occur regardless of breed, and monitoring for both therapeutic effect and adverse reactions is appropriate for all patients. The veterinarian's familiarity with breed-specific health tendencies informs overall patient assessment and treatment planning.

The MDR1 gene mutation that affects drug metabolism in certain breeds does not impact ceftiofur specifically, as this antibiotic is not a substrate for the P-glycoprotein transporter affected by the mutation. Breeds commonly carrying the MDR1 mutation include Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, Border Collies, and related herding breeds, as well as mixed breeds with herding dog heritage. While these dogs can safely receive ceftiofur, awareness of their MDR1 status is important for other medications they may receive. Genetic testing is available to identify affected dogs and can guide medication selection throughout their lives.

Size considerations are relevant for ceftiofur dosing and injection technique. Toy breed dogs weighing under ten pounds require precise dose calculations, as small errors in dosing can result in proportionally larger variations in drug exposure. The volume of injection is also a consideration in very small dogs. Giant breed dogs over one hundred pounds require larger total doses but follow the same weight-based dosing principles. The veterinary team will select appropriate syringe sizes and injection sites based on the individual dog's size. Injection site tolerance may vary among dogs of different sizes and body conditions.

Age considerations affect ceftiofur use across a dog's lifespan. Puppies have developing organ systems and may process medications differently than adult dogs. Very young puppies may require modified dosing approaches, and their response to treatment should be monitored carefully. Senior dogs may have age-related changes in kidney function or other organ systems that affect drug handling. Dogs over seven years of age for larger breeds, or over ten years for smaller breeds, may benefit from blood work assessment before treatment. The veterinarian will consider the patient's age and overall health status when developing the treatment plan.

Other cephalosporin antibiotics represent the most closely related alternatives to ceftiofur. First-generation cephalosporins such as cephalexin provide excellent gram-positive coverage and are available in oral formulations convenient for home administration. Second-generation cephalosporins like cefoxitin offer broader gram-negative activity. Other third-generation cephalosporins including ceftazidime and cefotaxime share similar broad-spectrum activity with ceftiofur, with ceftazidime having particular strength against Pseudomonas. Cefovecin, marketed as Convenia, is a veterinary cephalosporin with extended-release activity lasting up to two weeks from a single injection.

When cephalosporins are not appropriate or when broader or different antimicrobial coverage is needed, alternative antibiotic classes may be considered. Fluoroquinolones such as enrofloxacin and marbofloxacin provide broad gram-negative coverage and are available in oral formulations. Potentiated sulfonamides like trimethoprim-sulfamethoxazole offer broad-spectrum activity for many common infections. Amoxicillin-clavulanate combines a penicillin with a beta-lactamase inhibitor to overcome some resistance mechanisms. The choice among antibiotics depends on culture and sensitivity results, the site of infection, patient factors, and practical considerations such as route of administration and dosing frequency.

Complementary therapies may support dogs receiving ceftiofur for bacterial infections. Supportive care including adequate hydration and nutrition is important for recovery from infection. Probiotic supplements may help maintain or restore healthy intestinal bacterial populations during and after antibiotic therapy. Pain management may be appropriate depending on the type of infection being treated. Anti-inflammatory medications may be used for certain conditions but should be selected carefully to avoid drug interactions. The veterinarian coordinates all aspects of the treatment plan to optimize outcomes. Any changes to medications or addition of supplements should be discussed with the veterinarian to ensure safety and compatibility with the antibiotic regimen.